Pricing Log in Create free account
Friday 6 November 2026 Export NTRB’s income statement to Excel — free account

Nutriband Inc.

NTRB Healthcare Biotechnology

Nutriband Inc.’s revenue for fiscal 2026 (year ended January 2026) was $2.0 million, down 4.80% from fiscal 2025.

Revenue
−29.7%
EPS
+96.7%
Free cash flow
+55.5%
Total debt
−46.9%

Quarter to July 2026, against a year earlier

5.57 0.01 −0.18%
Market cap
$67.8M
P/E
0.0×
Fwd P/E
4.6×
Dividend yield
—
F-score
3/9
Altman Z
27.17
Beneish M
−3.51
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 56.81%

Capital & Financial Ratios $m

Size
Market Cap 67.77
Revenue ttm 1.62
Net income ttm (6.96)
Free cash flow ttm (3.63)
Net debt Q (3.40)
Valuation
P/E 0.00
Forward P/E 4.55
Price / sales 41.33 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 12.55 (above 6: high)
Financial health
Current ratio Q 4.21 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (181.76)
Growth
Revenue growth Q −29.72% (below 0%: shrinking)
Operating income growth Q +55.54% (above 0%: growing)
EPS, this year −526.26% (below 0%: weak)
EPS, next year A +125.32% (at or above 15%: strong)
Revenue, next year A +34.04% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +9.36%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 39.3×, against a ten-year median of 28.4×; over the ten years it ranged from 8.7× in 2023 to 417× in 2019.
P/S against its own 10 years 67.72%
10-year low 10-year high
P/B against its own 10 years 60.39%
10-year low 10-year high
EV/Sales against its own 10 years 67.01%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 0 4 5 3
Receivables 0 0 0 0
Inventory 0 0 0 0
Other — — — —
1 5 5 4
2024 2025 2026 Q'26
Payables 1 1 1 1
ST’ Debt — — — —
Other — — — —
1 1 1 1

Compound Annual Growth %

10y 5y 3y
Sales — 16.63% (0.69%)
Cash Flow — 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (1.25%) (7.98%)

Earnings Trends EPS, adjusted, against the consensus

Q4 FY26 Estimate −1.89 Actual −0.04

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q1 FY26 −0.13 −0.12 Beat by 0.01
Q2 FY26 −0.17 −2.12 Miss by 1.95
Q3 FY26 −2.13 −0.32 Beat by 1.81
Q4 FY26 −1.89 −0.04 Beat by 1.85

EPS $

Apr Jul Oct Jan Year
’26 (0.10) (0.07) — — —
’26 (0.12) (2.12) (0.32) (0.08) (2.58)
’25 (0.21) (0.15) (0.12) (0.51) (0.99)
’24 (0.13) (0.11) (0.22) (0.23) (0.69)
’23 (0.08) (0.12) (0.14) (0.21) (0.53)
’22 (0.04) (0.07) (0.23) (0.46) (0.81)
’21 (0.07) (0.03) (0.01) (0.33) (0.44)
Fiscal quarters ending in the months shown.

Revenue $m

Apr Jul Oct Jan Year
’26 0 0 — — —
’26 1 1 0 0 2
’25 0 0 1 1 2
’24 0 1 0 1 2
’23 0 0 1 1 2
’22 0 0 0 0 1
’21 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Apr Jul Oct Jan Year
’26 (1) (1) — — —
’26 (1) (1) (2) (1) (5)
’25 (1) (2) (1) (1) (5)
’24 (1) (1) (1) (1) (4)
’23 (1) (1) (1) (1) (3)
’22 0 0 (1) (1) (3)
’21 0 0 0 0 0
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Apr Jul Oct Jan Year
’26 (1) (1) — — —
’26 (1) (1) (2) (1) (5)
’25 (1) (2) (1) (1) (5)
’24 (1) (1) (1) (1) (4)
’23 (1) (1) (1) (1) (3)
’22 0 0 (1) (1) (3)
’21 0 0 0 0 0
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to January

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 TTM Jul ’26 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue — — 0 0 1 1 2 2 2 2 2 +35.3% 3 14 — +160.9%
Gross margin, % — — (17.53) (48.17) 33.52 35.46 36.08 41.34 34.74 27.80 33.14 +45.3 pt
EBT 0 (3) (3) (3) (3) (6) (4) (5) (10) (8) (7) +55.9%
EBT margin, % 0.00 0.00 (1,358.01) (734.38) (310.78) (434.26) (215.59) (263.05) (489.96) (404.07) (430.43) (404.1) pt
Net income 0 (3) (3) (3) (3) (6) (4) (5) (10) (8) (7) +55.9%
Per share, $
Per share, $ Revenue 0.00 0.00 0.04 0.06 0.14 0.18 0.25 0.26 0.20 0.18 0.13 n/m
Earnings (0.01) (0.12) (0.53) (0.43) (0.44) (0.81) (0.53) (0.69) (0.99) (2.58) (0.57) +95.8%
Cash flow (0.01) 0.00 (0.18) (0.14) (0.04) (0.35) (0.35) (0.44) (0.44) (0.44) (0.30) +61.2%
Capex 0.00 0.00 0.00 0.00 0.00 (0.01) (0.01) (0.01) (0.01) 0.00 0.00 n/m
Free cash flow (0.01) 0.00 (0.18) (0.14) (0.04) (0.36) (0.36) (0.45) (0.44) (0.44) (0.30) +61.2%
Book value 0.00 0.01 0.39 0.03 1.06 1.50 1.01 0.81 0.61 0.57 0.44 +104.9%
Shares, m 25 22 6 6 7 8 8 8 11 12 12 (8.0%)
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — 0.00 201.26 110.08 20.92 14.85 9.96 41.10 26.81 41.33 53.1
P/B — — 64.12 425.36 14.61 2.51 3.60 3.22 13.68 8.18 12.55 66.9
EV/Sales — — 0.00 201.42 110.25 17.60 13.97 9.79 39.14 24.61 39.27 52.1
EV/FCF — — (138.53) (83.08) (345.35) (8.66) (9.48) (5.70) (17.75) (9.75) (17.46) (77.3)
Cash, $m
Cash, $m Operating cash flow 0 0 (1) (1) 0 (3) (3) (4) (5) (5) (4) +48.3%
Capex — — 0 — — 0 0 0 0 0 0 +3.4%
Free cash flow 0 0 (1) (1) 0 (3) (3) (4) (5) (5) (4) +48.3%
Balance, $m
Balance, $m Working capital 0 0 0 (2) (2) 5 2 0 4 4 3 +78.3%
Net debt 0 0 0 0 0 (5) (2) 0 (4) (5) (3) +86.5%
Shareholders’ equity 0 0 2 0 7 12 9 6 6 7 5 +87.7%
Returns, %
Returns, % ROA (796.32) (2,637.61) (224.13) (108.75) (48.38) (56.23) (40.40) (64.63) (139.89) (400.11) (84.56) +396.2 pt
ROIC (1,454.81) (1,094.32) (105.69) (528.95) (22.51) (54.03) (41.82) (50.54) (295.49) (242.88) (227.92) +1,211.9 pt
ROE (2,608.62) (3,695.57) (263.74) (210.98) (80.49) (67.18) (43.89) (73.08) (162.94) (458.49) (100.79) +2,150.1 pt
People
People Employees 2 10 7 3 5 13 3 3 3 3 — +4.6%
Revenue/emp, $m 0.00 0.00 0.04 0.12 0.19 0.11 0.69 0.70 0.71 0.68 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Jan 2026 · latest quarter Jul 2026

Nutriband Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
OKYO OKYO Pharma Limited Sponsored ADR $73.5M — (loss-making) — — n/m +37.39% (above 0%: growing) 0.00% — Compare
MNOV MediciNova, Inc. $71.4M — (loss-making) — (loss-making) +240.56% (above 0%: growing) n/m +16.75% (above 0%: growing) 69.33% (554.36%) Compare
NTRB Nutriband Inc. $67.8M — (loss-making) 4.6× −29.72% (below 0%: shrinking) n/m +55.46% (above 0%: growing) 41.58% (203.57%)
ACRV Acrivon Therapeutics, Inc. $67.3M — (loss-making) — — n/m +12.59% (above 0%: growing) 0.00% 0.00% Compare
COYA Coya Therapeutics, Inc. $65.9M — (loss-making) — (loss-making) +48.96% (above 0%: growing) n/m −27.79% (below 0%: shrinking) 100.00% (2,891.67%) Compare
CNXU Conexeu Sciences Inc. $65.4M — (loss-making) — — n/m −1,084.33% (below 0%: shrinking) — 0.00% Compare
MAIA MAIA Biotechnology, Inc. $64.2M — (loss-making) — — n/m −63.23% (below 0%: shrinking) — 0.00% Compare
NORD Nordicus Partners Corporation $63.2M — (loss-making) — −99.58% (below 0%: shrinking) n/m +62.18% (above 0%: growing) 100.00% 0.00% Compare
CRBP Corbus Pharmaceuticals Holdings, Inc. $55.3M — (loss-making) — (loss-making) −92.09% (below 0%: shrinking) n/m −78.52% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $65.6M — — −21.57% — −7.60% 34.67% 0.00%

All 621 Biotechnology stocks →

Nutriband Inc. (NTRB) Latest News

13 Oct

Impact 3 · · GlobeNewswire

8 Oct

Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire
Impact 3 · · GlobeNewswire

1 Oct

Impact 4 · · GlobeNewswire

25 Sep

Impact 3 · · GlobeNewswire

8 Sep

Impact 3 ·

15 May

Impact 4 · · GlobeNewswire

30 Mar

Impact 4 · · GlobeNewswire

17 Feb

Impact 3 · · GlobeNewswire

30 Jan

Impact 4 · · GlobeNewswire

29 Jan

Impact 3 · · Simply Wall St.

1 Jan

Impact 3 · · TipRanks

31 Dec

Impact 3 · · GlobeNewswire

29 Dec

Impact 3 · · GlobeNewswire

18 Dec

Impact 4 ·
Impact 4 · · GlobeNewswire

24 Nov

Impact 3 · · NewsfileMT NewswiresSimply Wall St.Motley FoolSimply Wall St.MT NewswiresMotley Fool

28 Oct

Impact 4 · · GlobeNewswire
Impact 4 ·

27 Oct

Impact 4 · · GlobeNewswire

10 Oct

Impact 4 · · GlobeNewswire

24 Sep

Impact 3 · · GlobeNewswireSimply Wall St.ZacksSimply Wall St.

11 Sep

Impact 3 · · Simply Wall St.

10 Sep

Impact 4 · · GlobeNewswire

9 Sep

Impact 3 · · Zacks

3 Sep

Impact 3 · · GlobeNewswire

22 Aug

Impact 3 ·

8 Aug

Impact 4 · · GlobeNewswire

18 Jul

Impact 4 · · GlobeNewswire
stockrow.com/NTRB · Data as of Jul 31, 2026 · For information only; not investment advice. · © 2026 stockrow.com